Biofrontera Inc. (BFRI)

Biofrontera Inc. (BFRI) Healthcare & Pipeline Overview

Biofrontera Inc. is a US-based biopharmaceutical company specializing in commercializing prescription dermatological treatments, including Ameluz for actinic keratosis, the RhodoLED photodynamic therapy system, and Xepi for impetigo. The company focuses on addressing specific skin conditions within the specialty and generic drug manufacturing sector, leveraging its approved product portfolio for market penetration.

What Is the Investment Thesis for BFRI?

Biofrontera Inc. operates in the specialized US dermatological market, commercializing approved prescription products like Ameluz/RhodoLED for actinic keratosis and Xepi for impetigo. The company demonstrates a robust gross margin of 82.8%, indicating strong product profitability at the cost of goods sold level. Key value drivers include the continued adoption and market penetration of its photodynamic therapy system for actinic keratosis, a prevalent dermatological condition, and the expansion of Xepi's market share in impetigo treatment. Growth catalysts are tied to increasing prescription volumes and expanding the reach of its commercialization efforts within the US. However, investors should note the company's current negative profit margin of -25.7%, reflecting ongoing operational expenses associated with commercialization and market development. The company's market capitalization stands at $0.01 billion, positioning it as a smaller player in the biopharmaceutical space. Understanding these dynamics, including market potential for its niche products and the path to profitability, is crucial for evaluating its long-term prospects.

Based on FMP financials and quantitative analysis

BFRI Key Highlights

• Gross Margin of 82.8% indicates strong profitability at the product level, exceeding many industry benchmarks and reflecting efficient cost of goods management for its specialized dermatological products.
• Profit Margin of -25.7% highlights current operational losses, suggesting significant investments in commercialization, research, or administrative functions relative to revenue.
• Market Capitalization of $14.69M positions Biofrontera Inc. as a micro-cap biopharmaceutical company, indicating a smaller scale of operations and market valuation.
• Beta of 0.91 suggests the stock's volatility is slightly lower than the overall market, potentially appealing to investors seeking relatively stable performance within the healthcare sector.
• The company's focus on commercializing approved prescription drugs like Ameluz and Xepi for specific dermatological conditions underscores its targeted market strategy within the US healthcare landscape.

Who Are BFRI's Competitors?

BFRI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BFRI's Key Strengths?

• Approved product portfolio: Commercialization of Ameluz/RhodoLED for actinic keratosis and Xepi for impetigo provides established revenue streams.
• High Gross Margin: An 82.8% gross margin indicates strong product-level profitability and efficient cost management.
• Specialized market focus: Targeting specific dermatological conditions allows for concentrated expertise and commercial strategies.
• Integrated therapy offering: The combination of Ameluz and the RhodoLED lamp provides a comprehensive solution for actinic keratosis.

What Are BFRI's Weaknesses?

• Negative Profit Margin: A -25.7% profit margin indicates the company is not yet profitable, suggesting high operational costs relative to revenue.
• Reliance on specific products: Revenue generation is heavily dependent on the commercial success of Ameluz/RhodoLED and Xepi.
• Limited geographic scope: Operations are currently focused solely on the United States market.
• Smaller market capitalization: A $14.69M market cap suggests limited financial resources compared to larger biopharmaceutical companies.

What Could Drive BFRI Stock Higher?

• Increased prescription volumes for Ameluz/RhodoLED: Enhanced commercialization efforts and growing awareness among dermatologists could lead to higher adoption rates for actinic keratosis treatment.
• Expansion of Xepi market share: Continued marketing and sales initiatives could drive greater penetration of Xepi in the impetigo treatment market.
• Positive clinical data or regulatory updates for existing products: While not explicitly stated, any new data supporting efficacy or safety, or minor label expansions, could boost product appeal.
• Strategic partnerships or distribution agreements: Potential collaborations could enhance the reach and commercial success of Biofrontera Inc.'s product portfolio within the US.
• Operational efficiency improvements: Initiatives aimed at reducing operating expenses could improve the company's profit margin and financial performance.

What Are the Key Risks for BFRI?

• Financial-distress signal — its Altman Z-Score of -6.67 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Negative Profitability: The company's current -25.7% profit margin indicates ongoing operational losses, posing a risk to sustained financial health without a clear path to profitability.
• Intense Competition: The dermatological market is highly competitive, with numerous companies vying for market share, which could limit the growth potential of Biofrontera Inc.'s products.
• Product Concentration Risk: A significant portion of the company's revenue is derived from a limited portfolio of products (Ameluz/RhodoLED and Xepi), making it vulnerable to market shifts or competitive pressures impacting these specific treatments.
• Regulatory and Reimbursement Changes: Evolving healthcare regulations, drug pricing policies, or changes in insurance reimbursement could negatively impact the commercial viability and market access of its prescription products.
• Reliance on Licensor's Device: Ameluz's approval is tied to its use with a licensor's medical device (RhodoLED), introducing a dependency risk related to the availability, performance, or terms associated with this external component.

What Are the Growth Opportunities for BFRI?

• Enhanced Ameluz/RhodoLED PDT Adoption: Biofrontera Inc. has an opportunity to significantly increase the adoption of its Ameluz and RhodoLED lamp series for photodynamic therapy (PDT) in treating actinic keratosis on the face and scalp. The market for actinic keratosis treatments is substantial, driven by an aging population and cumulative sun exposure. By intensifying marketing and educational efforts directed at dermatologists, the company can expand the utilization of this approved, combination therapy, leveraging its efficacy and the convenience of the RhodoLED system to capture a larger share of the existing patient pool requiring lesion-directed and field-directed treatment.
• Increased Xepi Market Share: The commercialization of Xepi, a prescription cream for impetigo, presents a distinct growth avenue. Impetigo is a common bacterial skin infection, particularly among children, ensuring a consistent patient population. Biofrontera Inc. can focus on expanding Xepi's market penetration by highlighting its clinical profile and ease of use to pediatricians and general practitioners, in addition to dermatologists. Strategic promotional campaigns and managed care access initiatives could drive higher prescription volumes, allowing Xepi to gain a more substantial foothold in the topical antibiotic market for skin infections.
• Leveraging Integrated Solutions: The synergistic relationship between Ameluz and the RhodoLED lamp series offers a unique competitive advantage. By promoting these products as an integrated photodynamic therapy solution, Biofrontera Inc. can enhance their perceived value and streamline the treatment process for healthcare providers. This integrated approach can lead to increased sales for both components simultaneously, as the efficacy of Ameluz is tied to its use with the RhodoLED lamp. Emphasizing this comprehensive treatment system in commercial messaging can drive broader adoption and strengthen brand loyalty among dermatologists.
• Deepening US Market Penetration: Biofrontera Inc.'s existing focus on the United States market for its dermatological products provides a clear path for growth through deeper market penetration. Rather than immediate geographic expansion, the company can concentrate on optimizing its sales force effectiveness, expanding its reach to underserved regions or specific demographic segments within the US, and strengthening relationships with key opinion leaders and large dermatology practices. This strategy aims to maximize the commercial potential of its current approved portfolio by increasing prescription rates and market share across all states and territories where its products are available.
• Strategic Commercialization Efforts: Focused and data-driven commercialization strategies represent a significant growth opportunity. This involves optimizing sales and marketing spend, refining targeting strategies for healthcare professionals, and enhancing patient access programs. By analyzing market trends, competitor activities, and physician prescribing patterns, Biofrontera Inc. can tailor its commercialization efforts to maximize the uptake of Ameluz/RhodoLED and Xepi. Effective product positioning, robust medical education, and strategic pricing could drive sustained revenue growth from its specialized dermatological portfolio.

What Opportunities Does BFRI Have?

• Increased market penetration: Expanding the adoption of Ameluz/RhodoLED and Xepi within the existing US dermatological market.
• Growing demand for dermatology treatments: An aging population and increased awareness of skin conditions drive demand for specialized therapies.
• Leveraging existing commercial infrastructure: Optimizing sales and marketing efforts to maximize the reach and prescription rates of current products.
• Potential for strategic partnerships: Collaborations could enhance product distribution or expand market access.

What Threats Does BFRI Face?

• Intense competition: The specialty and generic drug market is highly competitive with numerous players developing dermatological treatments.
• Regulatory changes: Evolving healthcare regulations or reimbursement policies could impact product commercialization and profitability.
• Product lifecycle management: Patent expirations or the introduction of biosimilars/generics could erode market share for existing products.
• Economic downturns: Reduced healthcare spending or patient affordability issues could impact prescription volumes.

What Are BFRI's Competitive Advantages?

• Approved prescription drugs: Ameluz and Xepi have successfully navigated regulatory approval processes, creating a barrier to entry for new competitors.
• Specialized photodynamic therapy system: The combination of Ameluz with the RhodoLED lamp series offers a specific, approved treatment modality for actinic keratosis.
• Targeted market focus: Specialization in dermatological conditions allows for concentrated expertise and commercial efforts.
• Established commercial infrastructure: An existing sales and marketing apparatus in the US for its approved products facilitates market access and penetration.
• Intellectual property: While specific patents are not detailed, approved drugs typically benefit from intellectual property protection, offering a period of market exclusivity.

What Does BFRI Do?

Biofrontera Inc. is a biopharmaceutical company established in 2015 and headquartered in Woburn, Massachusetts, dedicated to the commercialization of pharmaceutical products for dermatological conditions across the United States. The company's core offerings address significant market needs in dermatology. A key product is Ameluz, a prescription drug specifically approved for use in combination with its licensor's medical device, the RhodoLED lamp series. This combination therapy is utilized for photodynamic treatment of mild-to-moderate actinic keratosis on the face and scalp, offering both lesion-directed and field-directed treatment options. Actinic keratosis is a common precancerous skin lesion, and the Ameluz/RhodoLED system provides a targeted therapeutic approach. Complementing its actinic keratosis franchise, Biofrontera Inc. also commercializes Xepi, a prescription cream indicated for the treatment of impetigo. Impetigo is a common bacterial skin infection, particularly prevalent in children, and Xepi provides a topical antibiotic solution. The company's strategy revolves around leveraging its approved product portfolio to penetrate the US dermatology market, focusing on direct commercialization efforts. With 92 employees, Biofrontera Inc. operates within the highly regulated healthcare sector, specifically targeting the specialty and generic drug manufacturing industry by bringing specialized treatments to market for dermatologists and their patients.

What Products and Services Does BFRI Offer?

• Commercializes pharmaceutical products for dermatological conditions in the United States.
• Offers Ameluz, a prescription drug for actinic keratosis, approved for use with a specific medical device.
• Provides the RhodoLED lamp series, a medical device for photodynamic therapy (PDT) of actinic keratosis.
• The Ameluz and RhodoLED combination treats mild-to-moderate actinic keratosis on the face and scalp.
• Commercializes Xepi, a prescription cream for the treatment of impetigo.
• Focuses on both lesion-directed and field-directed treatment approaches for actinic keratosis.
• Operates as a biopharmaceutical company since its incorporation in 2015.

How Does BFRI Make Money?

• Generates revenue through the sale of prescription pharmaceutical products, primarily Ameluz and Xepi.
• Commercializes medical devices (RhodoLED lamp series) that are integral to the application of its prescription drug Ameluz.
• Relies on a direct commercialization strategy within the United States, targeting dermatologists and other healthcare providers.
• Operates under a licensing agreement for Ameluz, which is approved for use in combination with a licensor's medical device.
• Focuses on specialty markets within dermatology, providing niche treatments for specific skin conditions.

What Industry Does BFRI Operate In?

Biofrontera Inc. operates within the Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector characterized by rigorous regulatory pathways and intense competition. The company's focus on dermatological conditions positions it within a market driven by an aging population, increasing awareness of skin health, and demand for specialized treatments. The market for actinic keratosis treatments, where Ameluz and RhodoLED compete, is significant due to the high prevalence of sun damage. Similarly, the market for impetigo treatments, addressed by Xepi, represents a consistent demand for topical antibiotics. Biofrontera Inc. differentiates itself through its specific approved products and their targeted applications, aiming to capture market share by offering specialized solutions. The industry is influenced by trends such as advancements in photodynamic therapy, the development of new topical formulations, and evolving payer landscapes, all of which impact commercialization success and competitive positioning.

Who Are BFRI's Key Customers?

• Dermatologists who prescribe Ameluz/RhodoLED for actinic keratosis and Xepi for impetigo.
• Patients diagnosed with mild-to-moderate actinic keratosis on the face and scalp.
• Patients requiring treatment for impetigo, a bacterial skin infection.
• Healthcare institutions and pharmacies that stock and dispense Biofrontera Inc.'s prescription products.
• General practitioners and pediatricians who may prescribe Xepi for impetigo.

Biofrontera Inc. Financial Trajectory

Biofrontera Inc. (BFRI) reported $10.1M in revenue for Q1 2026, a decline of 41.0% compared to the prior quarter. The company recorded a net loss of $4.8M, with diluted EPS of $-0.41. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BFRI averaged $-0.28 in diluted EPS.

Company Profile

Biofrontera Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Woburn, US. The company is led by CEO Hermann Luebbert. BFRI has traded publicly since 2021.

How Biofrontera Inc. Is Valued

Biofrontera Inc. carries a market capitalization of $14.69M, placing it in the micro-cap category. Relative to its peer group, BFRI's quantitative score of 21/100 is below the peer average of 66/100.

Key Financial Metrics

Return on assets is -44.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -82.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.20 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -107.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Biofrontera Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.67 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Biofrontera Inc. revenue of about $45.6M for fiscal 2026, with EPS near $-0.23.

Net buyingInsider Activity

Over the past six months, Biofrontera Inc. insiders filed 14 SEC Form 4 transactions — 2 sales and 12 purchases. On net that is roughly 555K shares acquired (about $286K) — insiders putting money in tends to read as conviction.

BFRI Financials

BFRI Latest News

BFRI Analyst Consensus

BFRI MoonshotScore

What Investors Ask About Biofrontera Inc. (BFRI) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources